A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- AbbVie
- Study ID
- NCT03886220
- Phase
- PHASE4
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - 51 Years
- Healthy Volunteers
- Not accepted
Interventions
- Elagolix — DRUGOral; Tablet
- Placebo — DRUGOral; Tablet
Study Details
The main objective of this study is to assess safety and efficacy of elagolix compared to placebo in reducing heavy menstrual bleeding (HMB) associated with uterine fibroids in premenopausal women. The primary hypothesis is that elagolix, compared to placebo, reduces HMB associated with uterine fibroids in premenopausal women.
Key Dates
- Start date
- Apr 12, 2019
- Status verified
- Mar 2022
- Primary completion
- Mar 31, 2021
- Completion
- Apr 28, 2021
Study Design
- Enrollment
- 82 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Elagolix 150 mgElagolix 150 mg once daily (QD)
- Experimental: PlaceboPlacebo QD
Primary Outcome Measure
Percentage of Participants Who Were Responders With Menstrual Blood Loss (MBL) Volume < 80 mL at Final Month and >= 50% Reduction in MBL Volume From Baseline to the Final Month [ Time Frame: From Month 0 (Baseline) to Final Month (up to Month 6) ]
Locations (45)
Find similar trials in Birmingham, AL
By research site
ACCEL Research Sites· Birmingham, ALUniversity of Alabama at Birmingham - Women's and Infant's Center· Birmingham, ALUnity Health- Searcy Medical Center· Searcy, ARGrossmont Ctr Clin Research· La Mesa, CAWomen's Health Care Research Corp· San Diego, CAAlliance for Multispecialty Research (AMR) - Fort Myers· Fort Myers, FL
Related Studies
- A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or EndometriosisPHASE3 · Recruiting · Sumitomo Pharma Switzerland GmbH · Mobile, Alabama
- An Open-Label Study to Evaluate the Effect of Elix Cycle Balance & Elix Daily Harmony on Fibroid-related SymptomsRecruiting · Zenchi, Inc. · Las Vegas, Nevada
- Transmucosal Uterosacral Electrical Stimulation for Pelvic Pain ReliefNot Yet Recruiting · Weill Medical College of Cornell University · New York, New York